Research has shown that even in melanoma patients with a high tumor mutational burden (TMB)—a factor typically associated with better response to anti-PD-1/PD-L1 therapy—the expected benefits of PD-1 blockade may not be realized [150, 151]. Here, PDCD1 is linked to neoplasm.